Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

Euro 246 M Funding Boosts Collaborative Projects between European Industry and Academia

  • Fifteen collaborative public-private research projects aiming to address bottlenecks in the pharmaceutical R&D process are to receive Euro 246 million from the European Commission (EC) and European Federation of Pharmaceutical Industries and Associations (EFPIA) companies, as part of the Innovative Medicines Initiative (IMI) imi.europa.eu, a public-private partnership between the EC and the European pharmaceutical industry.

    The EFPIA maintains the initiative, representing the first time that competing pharmaceutical companies will pool their resources, together with those of research organizations, patient groups, and other stakeholders, to develop generic knowledge.

    The overall aim of the IMI is to encourage the discovery and development of better drugs, and improve the competitiveness of the European pharma industry. The first 15 projects, selected from some 150 applications, will now go through the final negotiation stage. A second call for proposals in the fields of oncology, infectious disease diagnosis, chronic inflammatory diseases, and knowledge management, is scheduled for later this year.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »